Fibroscan / VCTE Interpretation by Decade of Life

What Fibroscan / VCTE Actually Measures

Vibration-Controlled Transient Elastography (VCTE), commercialized as Fibroscan by Echosens, quantifies liver stiffness by sending a low-frequency shear wave through the right hepatic lobe and measuring propagation velocity. The result is expressed in kilopascals (kPa). A stiffer liver, one with more fibrosis or inflammation, propagates the wave faster.

The device simultaneously captures the Controlled Attenuation Parameter (CAP), a proxy for hepatic steatosis reported in decibels per meter (dB/m). Both values are recorded in a single 10-minute outpatient session.

Why kPa, Not a Biopsy Score

A liver biopsy samples roughly 1/50,000 of total liver volume. VCTE interrogates a cylinder approximately 1 cm wide and 4 cm long, representing about 1/500 of liver volume. That 100-fold sampling advantage reduces variability, though it does not eliminate the confounding effects of acute hepatitis, right heart failure, extrahepatic cholestasis, or food intake within 2 hours of testing. EASL Clinical Practice Guidelines recommend fasting at least 2 hours before VCTE.

Technical Quality Gates

For a scan to be reportable, the success rate must be at least 60%, and the interquartile range divided by the median (IQR/M) must be below 30%. Results outside these thresholds should be repeated, not acted upon. The manufacturer's validation data and the 2021 EASL guidelines both specify these thresholds.

Fibroscan Normal Range: The Foundational Numbers

The most widely cited normative dataset comes from the European HEPAMET registry and the population-based studies used to derive EASL's 2021 guidance. In metabolically healthy adults with no alcohol use disorder and no chronic liver disease, LSM values cluster between 4.0 and 6.0 kPa.

The formal "normal" ceiling used in clinical practice is 7.0 kPa. Values between 7.0 and 8.0 kPa occupy a gray zone where mild inflammation, early fibrosis, or technical factors could each be responsible. Values at or above 8.0 kPa warrant further workup.

The CAP Companion Number

Steatosis grading by CAP:

| CAP (dB/m) | Steatosis Grade | Approximate % Hepatic Fat | |---|---|---| | <238 | S0 (none) | <5% | | 238 to 259 | S1 (mild) | 5 to 33% | | 260 to 291 | S2 (moderate) | 33 to 66% | | ≥292 | S3 (severe) | >66% |

Steatosis itself does not raise LSM proportionally, but severe steatosis (S3) can artificially raise LSM by 0.5 to 1.0 kPa in some patients, a factor to consider when interpreting borderline results. This attenuation-stiffness interaction is described in a 2022 Hepatology review of 1,773 consecutive VCTE scans.

Age-Stratified Interpretation: Decade by Decade

Age matters. Stiffness increases measurably across adulthood even in metabolically healthy livers, likely reflecting gradual accumulation of perisinusoidal collagen, reduced hepatic blood flow velocity, and declining autophagy efficiency. A cross-sectional study of 429 healthy blood donors (mean age 39 years, range 18 to 67) found LSM increased 0.05 kPa per year, P<0.001. The table below incorporates that age-drift estimate alongside EASL fibrosis cut-points.

Ages 18 to 29: The Metabolic Baseline Decade

Expected LSM in healthy young adults: 4.0 to 5.5 kPa. CAP is typically below 230 dB/m at this stage.

Any LSM above 6.5 kPa in a 20-something without obvious alcohol use or acute viral hepatitis deserves investigation. Wilson's disease, autoimmune hepatitis, and early NAFLD driven by ultra-processed diet are all described in patients under 30. An LSM of 8.0 kPa at age 24 is not "within age norms." It is an F2 signal regardless of decade.

The fibrosis cut-points do not shift with age. What shifts is the pre-test probability and the background population average.

Ages 30 to 39: When Metabolic Syndrome Begins Accumulating

Expected LSM in metabolically healthy adults: 4.5 to 6.0 kPa.

Visceral adiposity typically begins accumulating in the mid-30s, particularly in men, and MASLD prevalence rises sharply. The Global Burden of Disease 2019 analysis estimated MASLD prevalence at 31.7% in adults aged 30 to 44 worldwide. An LSM in the 7.0 to 8.0 kPa range at age 35 warrants a CAP review, fasting lipid panel, HbA1c, and ALT to differentiate early MASLD from incidental findings.

Ages 40 to 49: The Inflection Point for Fibrosis Risk

Expected LSM in metabolically healthy adults: 5.0 to 6.5 kPa.

By the mid-40s, cumulative metabolic exposure begins generating detectable periportal fibrosis in susceptible individuals. The NASH CRN cohort study (N=1,004) found that age ≥45 was an independent predictor of advanced fibrosis (F3, F4) in NAFLD, OR 2.3, 95% CI 1.5 to 3.5. An LSM of 8.5 kPa at age 47 carries meaningfully different clinical weight than the same reading at age 27.

Ages 50 to 59: Perimenopause, Testosterone Decline, and Stiffness Creep

Expected LSM in metabolically healthy adults: 5.5 to 7.0 kPa.

Estrogen exerts hepatoprotective effects via modulation of hepatic stellate cell activation. Its decline during perimenopause accelerates fibrosis progression in women with pre-existing steatosis. A longitudinal cohort study (N=382 postmenopausal women) found LSM increased 1.8 kPa over a 4-year follow-up period without any change in BMI or alcohol intake. Men experience analogous risk through declining testosterone and rising insulin resistance.

An LSM of 7.5 kPa in a 55-year-old woman with a CAP of 280 dB/m is an actionable MASLD finding, not a reassuring "age-appropriate" number. This is the decade where early MASH-related fibrosis first becomes clinically visible on population screening.

Ages 60 to 69: Distinguishing Fibrosis from Age-Related Stiffness

Expected LSM in metabolically healthy adults: 6.0 to 7.5 kPa.

Confounders multiply in this decade. Right heart failure (elevated hepatic venous pressure), type 2 diabetes, and polypharmacy all independently raise LSM without representing hepatic fibrosis. A 2019 study in Liver International (N=2,052) found that heart failure elevated LSM by a median of 4.6 kPa independent of fibrosis stage, P<0.001.

Before diagnosing F2 fibrosis based on an LSM of 8.2 kPa in a 64-year-old with compensated heart failure, clinicians should correct the cardiac cause first and repeat the scan within 3 to 6 months.

Ages 70 and Beyond: Longevity Context and the Sarcopenic Liver

Expected LSM in metabolically healthy older adults: 6.5 to 8.0 kPa (population average, not optimal target).

Age alone does not immunize anyone from MASLD progression. Sarcopenia-associated hepatic fat redistribution can raise CAP scores substantially even when total body weight is stable. The MASLD-sarcopenia interaction was quantified in a study of 643 adults over age 65: those with sarcopenia had a 2.4-fold higher odds of F2+ fibrosis vs. Age-matched non-sarcopenic controls.

The fibrosis thresholds (F2 = 8.0 kPa, F3 = 9.7 kPa, F4 = 13.0 kPa) remain fixed. The clinical question in a 74-year-old shifts from "what caused this?" to "does intervention reduce mortality risk given competing comorbidities?"

Optimal Fibroscan Target vs. The "Normal" Ceiling

The clinical "normal" of <7.0 kPa and the longevity-medicine optimal target are different numbers. The 7.0 kPa ceiling marks where disease likelihood starts to exceed noise. The optimal target is the LSM range associated with the lowest all-cause and liver-specific mortality in prospective cohort data.

A Swedish population cohort (N=2,114, median follow-up 9.7 years) found that all-cause mortality risk began rising at LSM ≥6.0 kPa, with the lowest mortality group sitting between 4.0 and 5.5 kPa. The HealthRX medical team uses 5.5 kPa as the internal optimal ceiling for patients under age 60, and 6.5 kPa for patients aged 60 and older.

The HealthRX Age-Stratified Fibroscan Target Framework

| Age Decade | Population Average (Healthy) | Optimal Target | Investigate If Above | |---|---|---|---| | 18 to 29 | 4.0 to 5.5 kPa | <5.0 kPa | 6.5 kPa | | 30 to 39 | 4.5 to 6.0 kPa | <5.5 kPa | 7.0 kPa | | 40 to 49 | 5.0 to 6.5 kPa | <6.0 kPa | 7.5 kPa | | 50 to 59 | 5.5 to 7.0 kPa | <6.5 kPa | 7.5 kPa | | 60 to 69 | 6.0 to 7.5 kPa | <7.0 kPa | 8.0 kPa | | 70+ | 6.5 to 8.0 kPa | <7.5 kPa | 8.5 kPa |

These "Investigate If Above" thresholds trigger next-step workup: FIB-4 score, ELF panel, MRI-PDFF, or hepatology referral. They are not synonymous with the EASL fibrosis staging cut-points, which apply universally at all ages.

MASLD Staging With VCTE

The AASLD 2023 guidance on MASLD (formerly NAFLD) integrates VCTE as a first-line non-invasive tool for fibrosis staging. The AASLD practice guidance states: "LSM by VCTE is the preferred non-invasive test for fibrosis staging in patients with suspected MASLD due to its high negative predictive value for advanced fibrosis."

Staging thresholds used in current practice:

• F0, F1 (none to mild): LSM <8.0 kPa
• F2 (significant): 8.0 to 9.6 kPa
• F3 (severe/bridging): 9.7 to 12.9 kPa
• F4 (cirrhosis): ≥13.0 kPa

A result between 7.0 and 8.0 kPa sits in the indeterminate zone. Combining VCTE with FIB-4 (a calculated score using age, AST, ALT, and platelet count) resolves most borderline cases without additional imaging. Meta-analysis of 17 studies (N=5,735) found that combining FIB-4 <1.3 with LSM <8.0 kPa had a negative predictive value of 97.4% for ruling out F3, F4 fibrosis.

When to Move Directly to Biopsy

Discordant VCTE and FIB-4 results (one normal, one abnormal) are the main indication to proceed to biopsy or MRE (magnetic resonance elastography). Biopsy also remains mandatory before starting resmetirom if VCTE is the sole evidence of MASH diagnosis.

Resmetirom (Rezdiffra): The Fibroscan Eligibility Threshold

Resmetirom is the first FDA-approved pharmacotherapy for noncirrhotic MASH with liver fibrosis. The FDA approved it in March 2024 based on the MAESTRO-NASH trial. MAESTRO-NASH (N=966) demonstrated that resmetirom 100 mg daily achieved MASH resolution in 29.9% of patients vs. 9.7% placebo, and fibrosis improvement of ≥1 stage without MASH worsening in 25.9% vs. 14.2% placebo, P<0.001 for both.

The approved label requires:

• Biopsy-confirmed MASH with fibrosis stages F2 or F3
• No decompensated cirrhosis

In clinical practice, an LSM ≥8.2 kPa on VCTE (corresponding to F2) combined with metabolic risk factors and elevated ALT creates sufficient pre-test probability to proceed to biopsy for formal MASH diagnosis before initiating resmetirom. Patients with an LSM below 8.0 kPa generally do not qualify for biopsy referral solely to pursue resmetirom eligibility.

GLP-1 Combination Data

Post hoc analyses of semaglutide 2.4 mg (Wegovy) data show liver stiffness reduction as a secondary endpoint. In the STEP-1 trial (N=1,961), 68-week treatment with semaglutide 2.4 mg produced 14.9% mean weight loss vs. 2.4% placebo, and secondary analyses showed LSM improvement in the subgroup with baseline LSM ≥7.0 kPa. Weight loss of 10% or more reduces LSM by an average of 1.8 to 2.5 kPa in MASLD populations, making GLP-1 therapy a meaningful LSM-lowering intervention even outside the resmetirom pathway.

Factors That Artificially Raise LSM

An elevated number does not automatically mean fibrosis. Several reversible conditions raise LSM without representing structural liver damage:

Acute Hepatitis and Inflammation

ALT above 100 U/L from any cause (alcohol binge, drug-induced liver injury, viral hepatitis flare) inflates LSM by 2 to 5 kPa. Repeat scanning after ALT normalization is standard before acting on the result. A prospective study of 200 patients with acute hepatitis found LSM decreased by a mean of 3.7 kPa after 4 weeks of treatment-induced ALT reduction.

Elevated Hepatic Venous Pressure

Right heart failure, tricuspid regurgitation, and Budd-Chiari syndrome all raise hepatic venous pressure and transmit stiffness to hepatic parenchyma. LSM can reach 15 to 25 kPa in decompensated heart failure without any underlying fibrosis. Always correlate with clinical history.

Recent Food Intake

Eating within 2 hours of scanning increases portal blood flow and raises LSM by a mean of 0.9 kPa. Fasting before the exam is a firm requirement, not a preference.

Obesity and Probe Selection

In patients with BMI >30 or skin-to-capsule distance >25 mm, the standard M probe underestimates depth and produces falsely elevated readings. The XL probe should be used. Failure to switch probes is one of the most common sources of spuriously elevated LSM in primary care settings.

Monitoring Frequency Recommendations

Scan frequency should match fibrosis stage and treatment status:

| Fibrosis Stage | Monitoring Interval | |---|---| | F0, F1, no metabolic syndrome | Every 3 to 5 years | | F0, F1, active MASLD, on treatment | Annually | | F2, no pharmacotherapy | Every 12 to 18 months | | F2, F3, on resmetirom or GLP-1 | Every 12 months | | F3, surveillance for cirrhosis development | Every 6 to 12 months | | F4, cirrhosis confirmed | Every 6 months (HCC surveillance required) |

EASL 2021 guidelines specify that patients with compensated cirrhosis on ultrasound surveillance should be scanned every 6 months with AFP co-testing.

Sex Differences in LSM Reference Ranges

Women have consistently lower mean LSM values than men in population studies, with a difference of approximately 0.4 to 0.7 kPa across most cohorts. A meta-analysis of 19 studies (N=12,804) confirmed that male sex was independently associated with higher LSM (standardized mean difference 0.38, 95% CI 0.22 to 0.54, P<0.001).

The practical implication: a 52-year-old man with an LSM of 7.3 kPa and a 52-year-old woman with the same reading occupy slightly different risk strata. Sex-specific reference ranges are not yet formally embedded in major society guidelines, but the HealthRX medical team adjusts the "investigate if above" threshold down by 0.3 kPa for women aged 40 to 60 to account for this difference.

The FIB-4 Index as a VCTE Companion

FIB-4 = (Age × AST) / (Platelet count × √ALT). A score below 1.3 reliably excludes advanced fibrosis; above 2.67 is high risk. Between 1.3 and 2.67, VCTE is the recommended next step rather than an immediate biopsy.

The AGA Clinical Practice Update (2023) states: "Sequential use of FIB-4 followed by VCTE is the recommended non-invasive strategy for risk stratification in patients with suspected MASLD in primary care and endocrinology settings." This two-step approach avoids both over-referral for biopsy and under-detection of clinically significant fibrosis.

Interpreting Your Fibroscan Report: A Practical Checklist

Before drawing clinical conclusions from a VCTE result, confirm each of these:

1. Was the patient fasting for at least 2 hours?
2. Was the IQR/M ratio below 30%?
3. Was the success rate at least 60%?
4. Was the correct probe used (M vs. XL)?
5. Were any acute confounders present (ALT >3x ULN, acute heart failure, recent alcohol)?
6. Is the CAP value consistent with the metabolic profile?
7. Is the result age- and sex-contextualized against population norms?

A result that passes all seven checks is a high-quality LSM. Act on it. A result that fails any of the first five items should be repeated under correct conditions before clinical decisions are made.